Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64041757 + Nivolumab in Advanced Lung Adenocarcinoma
NCT03371381Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of Pemlimogene merolisbac in lung adenocarcinoma, sponsored by Janssen Pharmaceutical. Started Jan 2018; status: terminated.
02
Drugs
Pemlimogene merolisbac
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03371381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371381.